Home/Pipeline/Frenelle PBC Program

Frenelle PBC Program

Substance Use Disorders

PreclinicalActive

Key Facts

Indication

Substance Use Disorders

Phase

Preclinical

Status

Active

Company

Frenelle Pharma

About Frenelle Pharma

Frenelle Pharma is a private, platform-based biotech company developing and commercializing its Faros™ long-acting injectable drug delivery technology. The company operates a unique business model of creating focused subsidiary ventures—SpineThera (Phase 2 for sciatica), Frenelle PBC (substance use disorders), and Anumio (animal health)—to advance programs from discovery to commercialization. With over a decade of R&D investment, proven preclinical data, and an active Phase 2 asset, Frenelle is positioned to disrupt markets in pain management, addiction, and veterinary medicine through improved therapeutic delivery.

View full company profile

Therapeutic Areas

Pain Management Substance Use Disorders Animal Health

Other Substance Use Disorders Drugs

Drug	Company	Phase	Status
Neuroplastogen Programs	Delix Therapeutics	Pre-clinical	Active
TAAR1 Program	Newleos	Preclinical	Active
Addiction Portfolio	Molteni Farmaceutici	Approved	Active
Conjugated Psiloc™	Cynaptec Pharmaceuticals	Preclinical	Active